BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardiac Science Inc. (CSCX) Reports Q2 Revenue of $36.1 Million


8/3/2009 8:04:38 AM

Bookmark and Share

BOTHELL, Wash., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Cardiac Science Corporation (Nasdaq:CSCX - News), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced today that revenue for the second quarter of $36.1 million was adversely impacted by its decision to hold shipments of AED products in accordance with its quality procedures. AED shipments have been withheld since late June to allow the Company to evaluate the quality of certain components. As a result of the delay, the Company did not ship approximately $3.0 million in AED products that otherwise would have shipped during the second quarter.

The Company continues to evaluate the operational and financial impact of the AED component issues, and has not yet determined when it will resume shipping. Management will provide an update on this issue when it releases its second quarter 2009 financial results and hosts its earnings call with analysts and investors at 4:30 p.m. Eastern Time on Monday, August 10, 2009.

To access the conference call, please dial 877.941.6011 and reference conference ID 4118733. Callers outside the U.S. can dial 480.248.5085. The call will also be webcast live at www.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at 800.406.7325 for U.S. callers or 303.590.3030 for those calling from outside the U.S. The password required to access the replay is 4118733#. An archived webcast will also be available at www.cardiacscience.com for 90 days.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(r), HeartCentrix(r), Powerheart(r), and Quinton(r) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, those that refer to Cardiac Science Corporation's evaluation of the operational and financial impact of the AED component issue. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future results or performance. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks, include those with respect to the quality of our processes, products, and services, and the implementation of voluntary actions or those taken at the request of regulatory authorities, as well as those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2008, as may be updated by subsequent Quarterly Reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on the deployment and use of AEDs worldwide, please subscribe to the Cardiac Science blog at http://www.cardiacscience.com/blog/ and follow us on Twitter at http://twitter.com/cardiacscience.

LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F Contact:

Cardiac Science Corporation Mike Matysik, Senior Vice President and CFO 425.402.2009

Allen & Caron Investor Contact: Matt Clawson 949.474.4300 matt@allencaron.com

EVC Group Inc. Media Contact: Christopher Gale 646.201.5431 203.570.4681 cgale@evcgroup.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES